[Adjuvant immunotherapy for patients with cancer of corpus uteri].
A randomized study was carried out of the efficacy of a new procedure of adjuvant immunotherapy for cancer of corpus uteri in conjunction with anticoagulant treatment. Ninety-seven patients (76-stage I-II and 21-stage III-IV) were inoculated tularemia booster (TB) and received fibrinolysin, pelentan and aspirin 15-20 days before combined treatment including uterine extirpation or extirpation with adnexa followed by telegammatherapy. Two groups of identical numbers of patients with an identical distribution of tumor progression stage were used as controls. No vaccination was carried out in one of them while TB inoculation was performed without anticoagulants in the other. A higher effectiveness of immunostimulation accompanied by anticoagulant administration was registered on the basis of the short-term (wound healing) and end results (relapse and metastasis frequency, duration of relapse-free survival and 2-, 3- and 5-year survival).
Adamian
R T
RT
V.A.Fanarjian Center for Oncology Research, Ministry of Health of the Republic of Armenia, Yerevan.
Movsesian
M A
MA
D000925:Anticoagulants / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D005260:Female; D005720:Gamma Rays; D006801:Humans; D016499:Radioimmunotherapy / Q000379:methods*; D016896:Treatment Outcome; D014406:Tularemia / Q000276:immunology; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D014945:Wound Healing
D000925:Anticoagulants; D001428:Bacterial Vaccines
Spocob ad'iuvantnoĭ immunoterapii bol'nykh rakom tela matki.